Celldex Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Celldex Therapeutics

28/02/2023 21:36

* Celldex Therapeutics Inc  CLDX.OQ  reported a quarterly
adjusted
loss of 56 cents​​ per share for the quarter ended in December.
The mean expectation of six analysts for the quarter was for a
loss of 59 cents per share.
    * Revenue rose 384.4% to $1.61 million from a year ago;
analysts
expected $264.00 thousand. 
    * Celldex Therapeutics Inc's reported EPS for the quarter
was a
loss of 56 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Celldex Therapeutics Inc shares had fallen by 3.4% this
quarter.
    * The company reported a quarterly loss of $26.49 million.
    * Wall Street's median 12-month price target for Celldex
Therapeutics Inc is $64.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
28 at 09:36 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.59          -0.56          Beat
 Sep. 30 2022      -0.58          -0.57          Beat
 Jun. 30 2022      -0.51          -0.59          Missed
 Mar. 31 2022      -0.45          -0.49          Missed